Summary
Introduction
Obesity affects one-third (34.9%) of adults in the USA (1) . Obesity is associated with an increased risk of a variety of diseases, including type 2 diabetes, dyslipidemia, hypertension, sleep apnea, osteoarthritis, cardiovascular disease and respiratory diseases (2) , as well as several types of cancers (3) . Obesity also poses a high economic burden on society, with medical costs associated with obesity totaling approximately $147bn per year in the USA (4).
The primary approach for obesity management and control is a change in lifestyle, but the benefits of pharmacotherapy for weight loss also have been demonstrated in clinical trials (5, 6) . The combined use of lifestyle modification and pharmacotherapy may work better in achieving clinically meaningful weight-loss goal (7) . According to the 2013 American Heart Association/American College of Cardiology/The Obesity Society guidelines (2), pharmacotherapy as an adjunctive treatment to comprehensive lifestyle changes may be an option for motivated patients with a body mass index (BMI) ≥30 kg m À2 or ≥27 kg m with ≥1 obesity-associated comorbidity. However, data are limited on the characteristics of real-world patients eligible for adjunctive pharmacotherapy and the predictors of adjunctive pharmacotherapy use. Such data may help develop effective strategies for weight-loss management and control. An analysis was thus conducted to describe the characteristics of real-world patients potentially eligible for adjunctive pharmacotherapy for weight loss and to identify the predictors of adjunctive pharmacotherapy use in the primary care setting in the USA.
Methods

Study population
A retrospective analysis was conducted using data from the GE Centricity® database, a de-identified longitudinal ambulatory care electronic medical record database with approximately 38 million patient records mainly from primary care providers in 49 states and Washington, DC, in the USA. At the time of the analysis, data were available through 30 September 2013. The distribution of age, gender and race in this database is generally similar to the US population.
Patients with BMI records were identified between 1 October 2002 and 30 September 2011 (index period). Patients were eligible if they had a BMI ≥30 kg m À2 or BMI ≥27 to <30 kg m À2 with ≥1 obesity-associated comorbidity (hypertension, dyslipidemia, or type 2 diabetes); were aged ≥18 years at the index date; had ≥12 months of continuous enrollment before and on the index date (baseline period) and had ≥12 months of continuous follow-up after the index date. Comorbid conditions were defined according to ICM-9-CM codes, medication use, or laboratory results using ICD-9-CM codes or algorithms from published studies and clinical guidelines (Table S1 ).
Study outcomes
The outcome variable for this analysis was the prescription of pharmacotherapy for weight loss within 12 months after the index date. Weight-loss drugs that were considered included benzphetamine, diethylpropion, orlistat, phendimetrazine, phentermine, sibutramine, lorcaserin and phentermine/topiramate. Bupropion/naltrexone and liraglutide 3.0 mg were not considered in this analysis, as they were approved in 2014, which was outside of the study period.
Statistical analysis
Patient characteristics were analysed using descriptive statistics in the overall study population and were stratified by the use of pharmacotherapy for weight loss within 12 months after the index date. Tests for differences between patients who received pharmacotherapy (the treated group) and those who did not receive pharmacotherapy (the untreated group) were performed using a 
Results
A total of 25,704,135 patients had BMI measurements at any time in the database, and 1,835,541 patients were included in the analysis after the application of the inclusion and exclusion criteria (Figure 1) at baseline. However, the use of weight-loss drugs at baseline was rare (0.6%).
There were also few patients who received pharmacotherapy for weight loss within 12 months after the index date (0.7%; n = 11,862). The percentage of patients who received pharmacotherapy within 12 months after the index date increased with increasing baseline BMI categories ( Figure 2 ). Among patients who received pharmacotherapy within 12 months after the index date, phentermine was the most frequently prescribed weightloss drug (62.9%), followed by orlistat (19.1%), sibutramine (14.7%), phendimetrazine (1.8%), diethylpropion (1.3%) and benzphetamine (0.2%). Lorcaserin and phentermine/topiramate, which were approved in the summer of 2012 (slightly overlapping with the study period), were not present in this analysis.
Compared with those who did not receive pharmacotherapy for weight loss within 12 months after the index date, patients who received treatment were predominantly female (84.3% vs. 58.2%), heavier (median BMI, 33.6 vs. 31.3 kg m À2 ), approximately 10 years younger (median age, 42 vs. 52 years), more commercially insured (70.1% vs. 50.4%) and were more likely to live in the Southern region of the USA (43.7% vs. 32.3%) at baseline (all P values < 0.0001) ( Table 1 ). The percentage of female patients decreased with increasing baseline BMI categories among patients who received pharmacotherapy, but increased with increasing baseline BMI categories among those who did not receive pharmacotherapy ( Figure 3a) . Patients who received pharmacotherapy were younger than their counterparts who did not receive pharmacotherapy, and this trend was observed across all baseline BMI categories ( Figure 3b ). Moreover, patients who received pharmacotherapy for weight loss within 12 months after the index date had a relatively lower percentage of hypertension, dyslipidemia, type 2 diabetes, osteoarthritis, cardiovascular diseases (coronary heart disease, congestive heart failure, cardiac dysrhythmia and stroke), chronic kidney disease and chronic obstructive pulmonary disease, but had a higher In multivariable analysis using a backward stepwise selection procedure, baseline patient characteristics that were significantly associated with the use of pharmacotherapy for weight loss in the following 12 months (positively or negatively) included BMI, age, gender, race, region, insurance, dyslipidemia, depression, osteoarthritis, sleep apnea, type 2 diabetes, cardiovascular disease, chronic kidney disease, use of anti-hypertensive drugs, anti-diabetic drugs, antidepressants, NSAIDs, or weightloss drugs ( Table 2 ). Use of weight-loss drugs at baseline was the strongest predictor of future weight-loss drug use -those who used weight-loss drugs at baseline were 99 times more likely to use weight-loss drugs in the next 12 months (Table 2) .
Discussion
In patients with overweight and ≥1 obesity-associated comorbidity or with obesity (who were therefore potentially eligible for pharmacotherapy for weight loss) in the primary care setting in the USA, comorbidities were common; however, pharmacotherapy use for weight loss within 12 months after the index date was infrequent (0.7%). In this study, patients who received pharmacotherapy were heavier, younger, predominantly female and more commercially insured at baseline compared with those who did not receive pharmacotherapy. Among the comedications evaluated, patients who received pharmacotherapy for weight loss were more commonly on antidepressants, NSAIDs, or weight-loss drugs, but were less frequently to have a personal history of cardiovascular disease or chronic kidney disease at baseline. Phentermine was the most frequently prescribed weightloss drug (62.9%) among those who were prescribed weight-loss medications. Prior use of weight-loss drugs was the strongest predictor of future weight-loss drug use as measured within 12 months after the index date.
Data on the characteristics of real-world patients eligible for weight-loss drugs have been limited. Consistent with the present study using prescription data in a US primary care setting, data from two US national surveys have also indicated that the use of pharmacotherapy for weight loss among eligible patients is low (8, 9) . In a retrospective cross-sectional analysis of pharmacy data from the 2002-2007 US Medical Expenditure Panel Survey, only 0.61% of eligible patients used weight-loss drugs (8) . In another retrospective cross-sectional analysis of self-reported data from the 2007-2008 National Health and Nutrition Examination Survey, only 2.2% of eligible patients reported the use of prescription weight-loss drugs, and 3.7% reported the use of non-prescription weight-loss drugs in the past year (9) . Similarly, an analysis of US outpatient weight-loss drug use using the Intercontinental Marketing Services (IMS) databases has shown that only approximately 2.74 million patients used weight-loss drugs in the USA in 2011, with the majority of patients receiving phentermine (2.43 million; 89%) (10) .
The low utilization of weight-loss drugs among patients eligible for pharmacotherapy for weight loss in the USA could be ascribed to a number of factors, such as moderate weight-loss effects, costs and limited insurance coverage for weight-loss drugs and safety concerns. In clinical trials, when used with lifestyle interventions, weight-loss drugs provided additional weight loss that ranged from approximately 3% to 9% of their initial weight at 1 year compared with placebo (6). However, the expectation for weight loss effects in patients is often higher (11) . Although weight-loss drugs significantly improve cardiovascular risk factors such as insulin sensitivity, glycemic control, dyslipidemia, hypertension and chronic inflammation in patients with overweight or obesity (12) (13) (14) (15) (16) , these health benefits may not be immediately obvious to patients. Also, no weight-loss drug has been with ≥1 obesity-associated comorbidity (hypertension, dyslipidemia, or type 2 diabetes).
Obesity 109 demonstrated to decrease cardiovascular morbidity or mortality (6) . Additionally, patients often prefer selfmanagement or over-the-counter options for weight control such as dietary changes, exercise, diet, or exercise weight-loss programmes and dietary and herbal weightloss supplements (11) . As mentioned previously, more patients who were eligible for pharmacotherapy reported the use of non-prescription weight-loss drugs (3.7%) than prescription weight-loss drugs (2.2%) in the past year in the USA (9) . Costs may also be a barrier, as most health plans in the USA provide limited or no coverage for weight-loss drugs. The Medicare prescription drug programme, for example, does not cover weight-loss drugs (17) . An analysis by Hampp et al., found that weight-loss drugs were mainly paid for with cash (10) . As shown in this study and in the Hampp study (10), phentermine was the most prescribed weight-loss medication in the USA. This may be due, at least in part, to its low cost and long clinical experience compared with other weight-loss drugs (6, 10) . Another contributing factor to the low utilization of pharmacotherapy for weight loss may be safety concerns, including the historical safety issues with weight-loss drugs such as fenfluramine (part of the fen-phen combination) (18) . This real-world study in the primary care setting, along with randomized clinical trials (12-16) and other observational studies (8) (9) (10) , have indicated that most users of prescription weight-loss drugs were predominantly women of a relatively younger age than non-users. This may be due, at least in part, to the fact that women, especially younger women, are more conscious of body weight, size and self-image (19) (20) (21) . The lower likelihood of pharmacotherapy use for weight loss in the elderly population might also be related to costs and the lack of Medicare coverage for weight-loss drugs. This hypothesis is supported by the finding in this study, which showed that Figure 3 Gender and age distribution of patients potentially eligible for pharmacotherapy for weight loss, a. Gender distribution of patients, b. Mean age at index of patients. Note: *BMI ≥27 to <30 kg m À2 (overweight) with ≥1 obesity-associated comorbidity (hypertension, dyslipidemia, or type 2 diabetes).
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The relationship between obesity and depression has been suggested to be bidirectional -obesity leads to depression, and conversely, depression results in obesity (22) . The present study has shown that antidepressant use was not uncommon in patients with overweight or obesity and those patients who used antidepressants or had depression were also more likely to use pharmacotherapy for weight loss. These findings further suggest that there is a complex relationship between obesity and depression.
Obesity and chronic pain often co-exist (23) . NSAIDs are commonly used for the management of chronic pain. Obesity has been shown to be associated with an increased risk of chronic pain, including low back pain, joint pain, headaches, fibromyalgia, widespread pain, abdominal pain, pelvic pain and neuropathic pain (23) . Obesity is a risk factor of osteoarthritis and is also associated with the severity and progression of the disease (23, 24) . Studies have shown that the frequency of chronic ) , osteoarthritis (no, yes), coronary heart disease (no, yes), congestive heart failure (no, yes), cardiac dysrhythmia (no, yes), stroke (no, yes), chronic kidney disease (no, yes), depression (no, yes), anxiety (no, yes), sleep apnea (no, yes), gastroesophageal reflux disease (no, yes), chronic obstructive pulmonary disease (no, yes), asthma (no, yes), anti-diabetic drugs (no, yes), antihypertensive drugs (no, yes), lipid-lowering drugs (no, yes), antidepressants (no, yes), non-steroidal anti-inflammatory drugs (no, yes) and weight-loss drugs (no, yes). A backward stepwise selection procedure was used to identify the variables for the final multivariable model, and the variables with P values of > 0.05 were excluded from the model. Use of pharmacotherapy for weight loss within 12 months after the index date (no, yes) was the outcome variable. ‡ Including Medicare part A, part C, private, or supplemental insurance. § Any time before or on the index date BMI, body mass index.
pain and osteoarthritis increases with increasing BMI (23, 24) . In this study, the finding that patients with overweight or obesity who took NSAIDs were more likely to use pharmacotherapy for weight loss suggests that patients with chronic pain conditions might be more motivated to lose weight for reducing obesity-associated chronic pain. Obesity is strongly associated with an increased prevalence of sleep apnea (25, 26) . Sleep apnea severely impairs health-related quality of life (26) . Weight loss has been shown to reduce the severity of sleep apnea (25, 26) . The present study has shown that patients with overweight or obesity who had sleep apnea were more likely to use pharmacotherapy for weight loss, suggesting that patients with sleep apnea might be more motivated to lose weight to help control sleep apnea.
This study has several strengths, including a large sample size and the utilization of real-world data from electronic medical records in the primary care setting. Additionally, there were little or no missing data on gender and age, two key covariates. However, this retrospective observational study also has some limitations. Although a multivariable analysis was performed to control for potential confounding of measured covariates, the residual confounding from confounders with measurement errors and the potential confounding by unmeasured covariates such as socioeconomic factors, use of non-prescription weight-loss medications and participation in dietary and physical activity programmes or time-dependent covariates cannot be excluded. The missing-indicator method was used for those covariates with missing data. The possibility that missing data in covariates might potentially influence the patterns of patient characteristics also cannot be excluded.
In summary, the findings from this large study suggest that few eligible patients in the primary care setting in the USA receive pharmacotherapy for weight loss. Patients who received pharmacotherapy tended to be heavier, younger, predominantly female, more commercially insured and used more antidepressants and NSAIDs than those who did not receive pharmacotherapy.
Conflict of Interest Statement
None
Funding
This study was supported by Takeda. 
Author contributions
S. Z. drafted the manuscript and designed the study. J. Y. conducted data analysis and contributed to study design. S. M. and J. L. contributed to data analysis. All authors contributed to data interpretation and had final approval of the submitted versions.
